Original Research Article
Year: 2021 | Month: January | Volume: 8 | Issue: 1 | Pages: 312-316
Incidence of Pyrazinamide Induced Hepatic Transaminitis in Elderly Patients
Vivek Kumar
Senior Resident, Department of Medicine, Madhubani Medical College & Hospital, Madhubani, Bihar
ABSTRACT
Objectives: The objective of this study was to determine the incidence of transaminitis in elderly patients treated with pyrazinamide and identify risk factors associated with the development of transaminitis.
Material and Methods: This was a retrospective clinical and epidemiological study of hepatotoxicity in patients of MDR tuberculosis. Two patient groups with and without occurrence of transaminitis were compared in this retrospective risk factor analysis, which was detected by an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >100 mg/dL.
Results: Total 92 patients were initially selected as per inclusion criteria, but 27 patients were excluded as all study details were not available with those. 65 patients were selected for the final analysis. 71.2±11.6 were the mean age of the total population and in which 40% were above 60 years of age. At initiation of pyrazinamide, measurements of both groups had AST and ALT that were within normal laboratory ranges (Table 2). The mean peak AST/ALT in the transaminitis group was 142± 42 mg/dL, with patients who did not develop transaminitis remaining within normal laboratory ranges which was 37±12 mg/dl. As compared to those with no transaminitis group, in the transaminitis group the overall percentage change in AST/ALT from start of pyrazinamide to peak was significantly higher.
Conclusion: We conclude that patients who are older and have concurrent pyrazinamide use have the highest risk of developing pyrazinamide induced transaminitis and should be monitored closely.
Keywords: Transaminitis, hepatotoxicity, elderly patients, pyrazinamide.
[PDF Full Text]